NeuroPace (NPCE) Asset Writedowns and Impairment (2020 - 2026)

NeuroPace's Asset Writedowns and Impairment history runs 7 years deep, the most recent figure standing at $76000.0 for Q1 2026.

• On a quarterly basis, Asset Writedowns and Impairment rose 72.73% year-over-year to $76000.0 in Q1 2026; TTM through Mar 2026 was $232000.0, a 21.89% decrease from a year earlier, with the FY2025 full-year figure at $200000.0, down 33.33% from the prior year.
• Asset Writedowns and Impairment rose to $76000.0 in Q1 2026 per NPCE's latest filing, from $60000.0 in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $107000.0 in Q3 2024 and bottomed at $34000.0 in Q1 2023.
• The 5-year median for Asset Writedowns and Impairment is $49000.0 (2025), against an average of $59705.9.
• Across the five-year window, Asset Writedowns and Impairment surged 241.67% in 2022 and plunged 58.54% in 2023, its largest moves.
• Year by year, Asset Writedowns and Impairment stood at $39000.0 in 2022, then soared by 64.1% to $64000.0 in 2023, then surged by 62.5% to $104000.0 in 2024, then plunged by 42.31% to $60000.0 in 2025, then rose by 26.67% to $76000.0 in 2026.
• Per Business Quant, the three latest NPCE Asset Writedowns and Impairment figures stand at $76000.0 (Q1 2026), $60000.0 (Q4 2025), and $47000.0 (Q3 2025).